ArticleBladder cancer (Amsterdam, Netherlands)2022

Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen.

Karin Holmsten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.